Education
About Us
Working with TipRanks
Follow Us
OKYO Pharma Limited Sponsored ADR (OKYO)
NASDAQ:OKYO
RESEARCH TOOLSreports
Top Page
OKYO Pharma Limited Sponsored ADR
(NASDAQ:OKYO)
35Underperform
Positive Factors
Clinical Trials
OK-101 has demonstrated favorable safety and tolerability in a Phase 2 trial in dry eye disease, with statistically significant improvements in symptoms such as stinging/burning and ocular pain.
Regulatory Approvals
OK-101 is the first NCP drug candidate that has received FDA IND clearance for clinical evaluation.
Negative Factors
Financial Risks
The company needs to raise additional capital within the next 12 months to fund operations.
OKYO Pharma Limited Sponsored ADR (OKYO) vs. S&P 500 (SPY)
Market Cap
$47.10M
Dividend YieldN/A
Average Volume (3M)250.56K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees8
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding33,886,314
10 Day Avg. Volume174,137
30 Day Avg. Volume250,565
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.00Price Target Upside414.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
OKYO Pharma Limited Sponsored ADR Business Overview & Revenue Model
Company DescriptionOKYO Pharma Limited Sponsored ADR (OKYO) is a biotechnology company focused on the discovery and development of innovative therapeutics for inflammatory diseases and pain management. Operating primarily in the biopharmaceutical sector, the company is committed to leveraging its expertise in drug development to address unmet medical needs, particularly in the fields of ophthalmology and chronic pain.
How the Company Makes MoneyOKYO Pharma Limited generates revenue primarily through the development and commercialization of its therapeutic products. The company's revenue model is based on licensing agreements, partnerships, and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on product sales. Additionally, OKYO may engage in research and development collaborations, receiving funding and resources to advance its drug candidates. Other potential revenue streams include government grants and research funding to support the company's innovative pipeline. However, as a company in the development stage, its earnings are significantly influenced by its ability to successfully bring its drug candidates to market and establish beneficial partnerships.
OKYO Pharma Limited Sponsored ADR Financial Statement Overview
Summary
OKYO Pharma Limited faces significant financial challenges. The absence of revenue generation, combined with negative equity and persistent cash outflows, highlights substantial financial risk. Ongoing R&D investments without corresponding revenue or profitability improvements remain key concerns.Income Statement
OKYO Pharma Limited has shown no total revenue over the past years, reflecting the challenges in generating sales typical in the biotechnology industry. Net income remains negative, indicating ongoing operational and developmental expenses without offsetting revenue.10
Very Negative
Balance Sheet
The balance sheet indicates a concerning negative stockholders' equity, which is a risk factor for financial stability. The total liabilities exceed total assets, which may affect the company's ability to raise capital. The debt-to-equity ratio cannot be calculated due to negative equity, further highlighting financial risk.20
Very Negative
Cash Flow
OKYO's cash flow is characterized by negative operating cash flow and free cash flow, suggesting significant cash burn typical for R&D-focused biotech firms. However, the company has managed to secure financing inflows, which partially mitigates cash flow concerns.15
Very Negative
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -16.54K | ― | ― | ― | -13.09K | ― | EBIT |
| -6.22M | ― | -13.19M | -6.22M | ― | -1.52M | EBITDA |
| -6.20M | ― | -13.18M | -6.22M | -3.35M | -1.51M | Net Income Common Stockholders |
| -5.43M | ― | -13.27M | -5.43M | -3.35M | -1.54M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 627.56K | 826.85K | 4.05M | 2.70M | 6.89M | 234.96K | Total Assets |
| 759.86K | 1.54M | 5.20M | 4.30M | 7.09M | 597.40K | Total Debt |
| 0.00 | 0.00 | 2.22M | 0.00 | 98.76K | 31.62K | Net Debt |
| -627.56K | -826.85K | -1.83M | -2.70M | -6.79M | -203.34K | Total Liabilities |
| 426.72K | 7.42M | 7.26M | 1.35M | 1.77M | 737.20K | Stockholders Equity |
| 333.14K | -5.88M | -2.05M | 2.95M | 5.32M | ― |
| Cash Flow | Free Cash Flow | ||||
| -3.02M | -9.49M | -7.70M | -5.47M | -1.61M | -1.20M | Operating Cash Flow |
| -5.35M | -9.49M | -7.70M | -5.47M | -1.60M | -1.20M | Investing Cash Flow |
| 0.00 | 0.00 | -5.92K | -1.67K | -18.11K | -132.67K | Financing Cash Flow |
| 1.41M | 6.21M | 9.32M | 2.15M | 7.83M | 963.31K |
OKYO Pharma Limited Sponsored ADR Technical Analysis
Positive
1.36
Price Trends
1.14
Positive
1.11
Positive
1.15
Positive
Market Momentum
0.08
Negative
67.96
Neutral
83.75
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OKYO, the sentiment is Positive. The current price of 1.36 is above the 20-day moving average (MA) of 1.20, above the 50-day MA of 1.14, and above the 200-day MA of 1.15, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 67.96 is Neutral, neither overbought nor oversold. The STOCH value of 83.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OKYO.
OKYO Pharma Limited Sponsored ADR Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $1.22B | ― | -95.21% | ― | 9.03% | -25.00% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
48 Neutral | $487.29M | ― | -43.42% | ― | -5.97% | -25.87% | |
44 Neutral | $395.27M | ― | -58.54% | ― | ― | -47.28% | |
42 Neutral | $129.44M | ― | -98.10% | ― | -58.64% | -40.05% | |
35 Underperform | $47.10M | ― | 0.00% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
OKYO
OKYO Pharma Limited Sponsored ADR
1.39
-0.06
-4.14%
EYPT
EyePoint Pharmaceuticals
7.35
-14.74
-66.73%
ALDX
Aldeyra Therapeutics
6.92
4.02
138.62%
OCUL
Ocular Therapeutix
8.51
-1.08
-11.26%
EDIT
Editas Medicine
1.47
-7.12
-82.89%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.